Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00481455 · ClinicalTrials.gov registry record · Phase 2

Phase 2 Study of Panzem Nanocrystal Colloidal Dispersion (NCD) in Combination With Fixed-Dose Temozolomide to Patients With Recurrent Glioblastoma Multiforme (GBM)

A Phase 2 study of Recurrent Glioblastoma Multiforme, sponsored by CASI Pharmaceuticals.

Completed
Registry status
Phase 2
Development phase
15
Enrollment target
1
Study location

NCT00481455 is a Phase 2 study of Recurrent Glioblastoma Multiforme that has completed, run by CASI Pharmaceuticals. The registered enrollment target is 15 participants, below the 101-participant average among 6 other Recurrent Glioblastoma Multiforme trials with a reported enrollment target (85% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00481455, a Phase 2 study of Recurrent Glioblastoma Multiforme, has completed, sponsored by CASI Pharmaceuticals.

COMPLETED
Registry status
Phase 2
Development phase
15 participants
Enrollment target
1
Study location

Study Summary

The purpose of this study is to evaluate the anti-tumor activity and safety of Panzem NCD given in combination with daily oral fixed-dose temozolomide in patients with recurrent glioblastoma multiforme.

Conditions Studied

Recurrent Glioblastoma Multiforme

Interventions

  • DRUG Temozolomide
  • DRUG Panzem NCD

Study Locations (1)

North Carolina

  • The Brain Tumor Center, Duke University Medical Center - Durham

Trial Details

FieldValue
Enrollment Target 15 participants
Start Date 2007-04
Est. Completion 2008-10
Phase Phase 2

Sponsor

CASI Pharmaceuticals

6 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT00481455

The ClinicalTrials.gov registry entry for NCT00481455 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 101-participant average among 6 other Recurrent Glioblastoma Multiforme trials with a reported enrollment target (85% lower). The listed sponsor is CASI Pharmaceuticals, which has 6 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Recurrent Glioblastoma Multiforme appearing as the primary indexed condition, and to 2 interventions - of which Temozolomide is the first listed.

NCT00481455 reports 1 study location spanning 1 distinct geographic area - top geographies include North Carolina.

Frequently Asked Questions

What is clinical trial NCT00481455 about?

NCT00481455 is a clinical study titled "Phase 2 Study of Panzem Nanocrystal Colloidal Dispersion (NCD) in Combination With Fixed-Dose Temozolomide to Patients With Recurrent Glioblastoma Multiforme (GBM)". The purpose of this study is to evaluate the anti-tumor activity and safety of Panzem NCD given in combination with daily oral fixed-dose temozolomide in patients with recurrent glioblastoma multiforme.

What is the current status of trial NCT00481455?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 15 participants. The study started on 2007-04. Estimated completion is 2008-10.

What conditions does trial NCT00481455 study?

This clinical trial studies the following conditions: Recurrent Glioblastoma Multiforme.

What interventions are being tested in trial NCT00481455?

The interventions under investigation include: Temozolomide (DRUG), Panzem NCD (DRUG).

Who is sponsoring clinical trial NCT00481455?

This trial is sponsored by CASI Pharmaceuticals, which has 6 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00481455 being conducted?

This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Recurrent Glioblastoma Multiforme

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Recurrent Glioblastoma Multiforme

All registered trials for this condition

North Carolina

All trials with a study site in North Carolina

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.